NHSBT Finance Report

February 2023

Contents	Page
Executive Summary	2
Financial Performance Headlines	3-4
NHSBT – Summary I&E Statement	5
Divisional I&E statements	6-9
Cash & Debtors	10
Contribution Statement	11



Executive Summary

Revenue Update

Blood and Group Services –We continue to remain confident that the 2022/23 financial plan will be delivered within the agreed resourcing envelope. Since the quarter 3, we have seen a small improvement to the forecast financial position, as further transformation reductions are crystalised. Consequently we head into 2023/24 with a higher cash reserve (c£13m versus a £10m working capital threshold), providing a ring fenced contingency to mitigate underlying risks in Blood and Donor Experience next year.

Looking forward to 2023/24, the budgets have now been finalised and will be presented at the March Board for approval. The proposed budget, based on the 8% price increase agreed at the National Commissioning Group, combined with a £12m non recurring transformation budget, has resulted in a break even position for Blood and Group. However, please note that the outlook for 2023/24 remains extremely challenging with limited headroom, the contingency created utilising the cash carried forward from 2022/23, together with a small reserve built into the plan will provide a buffer against uncertainties.

Organ Donation and Transplantation - The latest forecast for ODT predicts an end of year surplus of £1.2m (against a -£1.8m budget deficit). The current cash flow assumes we will draw down the fully allocated programme funding of £86.3m (which includes stem cells, DCD Hearts and pension funding) and can carry forward our cash reserves into next year (subject to DHSC agreement/contingency versus higher volumes, pay inflation and DCD Hearts run off costs). The outlook for 2023/24 results in an operating deficit, as an increasingly growing cost base is met by flat funding.

Tissue and Eye Services – At M11, the latest view reports a deterioration of the year end position. TES now foresee a contribution shortfall of c£1.9m (versus the Q3 forecast of £1.7m), with the incremental increase driven by higher usage of overtime to maintain service level. This contribution gap is being funded by Blood and Group reserves. An income reset planned for 2023/24, is dependent upon on the Pathway for Corneas and also increased pricing to achieve contribution. However if this plan cannot be fully delivered, the risk to Blood cash reserves remains.

Clinical Services – The most recent view continues to forecast a higher than plan surplus for CS, reporting contribution increases across most business units. However, CBC and Stem Cells are currently being cross-subsidised by other business units, as they report slippages in planned activity. Similarly with Blood, the Clinical Services 2023/24 pricing envelope was approved at the February National Commission Group. The expectation is that the planning volumes and reset prices will ensure that each of the business units achieve their agreed level of contribution.


Plasma for Medicines – the 2022/23 financial plan is being fully funded by a combination of cash reserves and plasma for Diagnostics income. Reductions in transformation expenditure and increased income from activity has resulted in higher cash reserves being carried into 2023/24. These reserves will be utilised and consequently results in a balanced budget for next year. Discussions are still ongoing with NHS England to finalise an SLA which will fully fund collection costs once the funding has been utilised.

Capital Update

The year to date spend against the capital allocation is £6.1m, with a full year forecast of £10.5m (versus £21m originally requested). Following work with the capital leads the indicative plan for 2023/24 totals £21m, which is made up of operational capital for the replacement / replenishment of assets, maintenance of our estate and investment within DDTS including Blood Tech Modernisation.

2022/23 NHSBT Financial Performance Headlines - February 2023

Year to date surplus of £6.2m for NHSBT overall, £4.0m ahead of plan



2022/23 NHSBT Financial Performance Headlines – February 2023

		Blood/Group	+£3.6m	Lower transformation spend.	-
Year to	£6.2m surplus VS	Plasma	-£0.3m	The adverse position reflects an increase in funding available to c/fwd. into 2023/24, arising from lower than expected overhead costs charged (and with the off-setting benefit) through the ABC contribution statement.	
Date	£2.2m budget surplus	Clinical Services	-£0.3m	BAU – business units are reporting £1.3m ahead of plan. Transformation - £1.6m expenditure year to date (budget profiled into M12)	
		OTDT	+ £1.0m	ODT (+£2.5m) – lower activity related expenditure combined with increased funding from devolved nations. TES (-£1.6m) – Cornea income shortfall.	-
		Blood/Group	-£2.6m	Pressures in Blood Supply, partially offset by Change Programme underspends – detail on 5 & 6.	
	£8.1m deficit				

Full Year	£8.1m deficit forecast	Plasma	-£0.3m	ABC allocation £0.3m lower than budget estimates (carry forward as cash to 2023/24).	
Forecast (at Q3)	VS £8.1m deficit	Clinical Services	+£2.3m	Lower costs due to unfilled vacancies and reduced transformation spend.	
	budget	OTDT	+£0.7m	ODT (+£2.4m) – Lower activity related expenditure. TES (-£1.7m) – Cornea activity lower than plan.	

Occli		Debtor Days	18 days – ahead of target (22 days)	
Cash and	Cash balance £65m	90+ day overdues	£0.6m (within £0.5m - £1.0m target range).	
Debtors		Cash	Cash balance forecast at the end of March 2023 is £47m. Notionally; Blood £13.7m, CS £7.9m, ODT £11.3m, Plasma £14.6m	

NHSBT Summary I&E statement - February 2023

	Feb			WT	E		Year to Date			Full Year		
Budget	Actual	Variance	Blood and Group	Budget	Actual	Budget	Actual	Variance	Prev. Yr Actual	Budget	Q3 Forecast	Variance
1,036	933	(102)	Programme Funding - Corporate	4		11,392	10,267	(1,126)	11,461	12,428	11,200	(1,228)
25,271	25,406	135	Blood & Components Income			281,064	280,745	(319)	292,274	306,827	306,427	(400)
280	365	85	Blood Supply Other Income			3,193	3,738	544	3,864	3,512	4,017	505
500 27,087	376 27,080	(124) (6)	Group Services Income Blood and Group Income	-		<u>5,581</u> 301,231	5,629 300,378	48 (852)	<u>5,272</u> 312,872	6,091 328,857	6,379 328,023	<u>288</u> (834)
21,001	27,000	(0)		_		301,231	300,378	(052)	512,012	520,057	520,025	(034)
(134)	(661)	(527)	Blood Supply Cost of Sales	0	0	315	797	482	(2,305)	0	1,080	1,080
(13,196)	(14,244)	(1,048)	Blood Supply Operations	2,462	2,576	(150,337)	(158,231)	(7,894)	(163,543)	(163,952)	(172,927)	(8,975)
(14,992)	(15,334)	(342)	Group Services	1,222	1,152	(166,860)	(164,209)	2,652	(168,895)	(182,936)	(183,078)	(142)
(1,556) (29,877)	(1,450) (31,689)	106 (1,812)	Change Programme Blood and Group Expenditure	0 3,685	35 3,764	(15,638) (332,520)	(6,381) (328,024)	9,257 4,496	(12,213) (346,956)	(16,999) (363,886)	(10,753) (365,677)	<u>6,246</u> (1,791)
(29,077)	(31,009)	(1,012)		3,005	3,704	(332,320)	(328,024)	4,490	(340,930)	(303,880)	(305,077)	(1,791)
(2,791)	(4,608)	(1,818)	Blood and Group Total	3,685	3,764	(31,290)	(27,645)	3,644	(34,085)	(35,029)	(37,654)	(2,626)
			Plasma for Medicine	T .								
1,176	346	(829)	Programme Funding - Plasma	-		12,931	11,996	(935)	29,483	14,107	8,646	(5,461)
682	1,278	596	Plasma for Diagnostics Income	_		6,818	8,385	1,567	1	7,500	9,840	2,340
1,857	1,624	(234)	Plasma Funding	_		19,749	20,381	632	29,484	21,607	18,486	(3,121)
0	0	0	Plasma for Medicine Cost of Sales	0	0	0	0	0	1,076	0		
(851)	(655)	196	Plasma for Medicine	122	149	(9,671)	(10,578)	(907)	(29,484)	(16,493)	(8,673)	2,303
(851)	(655)	196	Plasma Expenditure	_		(9,671)	(10,578)	(907)	(28,408)	(16,493)	(13,672)	2,821
1,006	969	(38)	Plasma for Medicine Total	122	149	10,078	9,803	(275)	1,076	5,113	4,813	(300)
			Clinical Services	-								
374	347	(27)	Programme Funding - Clinical Services	-		4,115	3,815	(300)	4,162	4,489	4,162	(327)
5,789	6,186	397	Clinical Services Income			65,550	65,561	10	69,057	72,420	73,269	849
6,163	6,533	370	Clinical Services Income	_		69,665	69,376	(290)	73,219	76,909	77,431	522
(5,402)	(5,575)	(173)	Clinical Services Operations	803	769	(60,298)	(58,721)	1,577	(59,448)	(65,839)	(65,596)	243
(0,402)	(117)	(117)	Clinical Services Change Programme	0000	7	(00,200)	(1,614)	(1,614)	(1,671)	(3,751)	(2,234)	1,517
(5,402)	(5,692)	(290)	Clinical Services Expenditure	_		(60,298)	(60,334)	(37)	(61,119)	(69,590)	(67,830)	1,760
761	841	81	Clinical Services Total	803	776	9,367	9,041	(326)	12,101	7,319	9,601	2,282
			Organ Donation & Transplantation									
6,665	7,039	374	Programme Funding (DHSC and Other UK Health Authorities)	-		73,317	77,517	4,199	81,504	79,983	84,539	4,556
170	170	0	Programme Funding - Opt Out			1,871	1,871	0	0	2,041	2,041	0
284	288	4	NHSE Funding	_		3,121	3,176	55	1,921	3,404	3,640	236
7,119	7,497	378	ODT Income	_		78,309	82,564	4,254	83,425	85,428	90,220	4,792
(5,615)	(5,720)	(105)	Organ Donation and Transplantation Operations	490	473	(65,150)	(64,262)	888	(63,376)	(71,926)	(70,713)	1,213
(362)	(765)	(403)	Organ Donation and Transplantation Change Programme	30	25	(3,985)	(6,609)	(2,624)	(10,500)	(4,488)	(8,102)	(3,614)
(5,977)	(6,485)	(507)	ODT Expenditure	_		(69,135)	(70,871)	(1,736)	(73,876)	(76,414)	(78,815)	(2,401)
1,142	1,012	(129)	ODT Total	520	498	9,174	11,693	2,519	9,550	9,015	11,406	2,391
			Tissues and Eye Services	-								
1,696	1,257	(439)	Tissue & Eye Services Income	-		16,283	14,894	(1,389)	15,062	17,937	16,236	(1,701)
46	42	(5)	Programme Funding - Tissue and Eye Services	_		508	458	(50)	0	554	500	(54)
1,742	1,299	(443)	TES Income	_		16,791	15,352	(1,439)	15,062	18,491	16,737	(1,755)
(1,060)	(1,193)	(133)	Tissue and Eye Services Operations	153	150	(11,938)	(12,060)	(122)	(12,468)	(13,043)	(12,975)	68
(1,060)	(1,193)	(133)	TES Expenditure			(11,938)	(12,060)	(122)	(12,468)	(13,043)	(12,975)	68
683	106	(576)	TES Total	153	150	4,853	3,292	(1,561)	2,595	5,449	3,762	(1,687)
				_								
10.005	11.000	0.5	NHSBT Summary	_		(05 - 15	400.051	0.055	=	FO (O C F	F00.00-	(222)
43,968 (43,167)	44,033 (45,713)	65 (2,546)	Income Expenditure	5,283	5,336	485,745 (483,562)	488,051 (481,867)	2,306 1,695	514,063 (522,826)	531,293 (539,426)	530,897 (538,969)	<mark>(396)</mark> 457
(43,167) 801	(45,713) (1,680)	(2,546)	NHSBT Surplus/(Deficit)	5,283 5,283	5,336	(483,562) 2,183	<u>(481,867)</u> 6,184	4,001	(522,826)	(539,426) (8,133)	(538,969) (8,072)	<u>457</u> 61
001	(1,000)	(2,400)			0,000	2,105	0,104	4,501	(0,704)	(0,100)	(0,012)	

Blood and Group - February 2023

Blood Supply	W	ΓE	Year t	o Date Act	tual	Full	Year Forec	ast			Dod		ice vs	Domo	nd	
(£)m	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.			Reu	Cell Pr	ice vs	Dema	na	
Blood and Component Income			281.1	280.7	(0.3)	306.8	306.4	(0.4)	1,550							
Other Blood Supply Income			3.2	3.7	0.5	3.5	4.0	0.5	ີ ຊີ 1,500					£138.83	£145.99	£153.30
Total Income			284.3	284.5	0.2	310.3	310.4	0.1	.0 E 1,450	_	£124.46	£128.99	£133.44			
Cost of Sales - Blood Component Stock Movement			0.3	0.8	0.5	0.0	1.1	1.1		£120.00						
Blood Donation	1,420	1,519	(69.2)	(73.2)	(4.1)	(75.3)	(80.0)	(4.7)	e 1,350						_	_
Manufacturing, Testing & Issue	732	738	(60.9)	(63.0)	(2.2)	(66.4)	(68.9)	(2.5)		_					_	_
Logistics	310	320	(20.3)	(21.9)	(1.6)	(22.2)	(24.0)	(1.9)	2 1,250							
Total Expenditure	2,462	2,576	(150.0)	(157.4)	(7.4)	(164.0)	(171.8)	(7.9)	1,200	2016/17	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23
											-	-	Demand (n		,	,25

Blood Supply Operating Surplus/(Deficit)	2,462 2,576 134.2 127.0 (7.2) 146.4 138.6 (7.8)	
Group Services (incl. Change Programme)	1,222 1,185 (165.5) (154.7) 10.8 (181.4) (176.3) 5.2 Group Services detail on page 6	
Blood and Group Surplus/(Deficit)	3,685 3,761 (31.3) (27.6) 3.6 (35.0) (37.7) (2.6)	

Year to date, Blood Supply are reporting £7.2m adverse cost variance against plan driven by a combination of factors;

- Impact of the higher than budget pay inflation
- Higher use of overtime and temporary staff in Collections and Manufacturing
- Inflationary fuel pressures and increased usage of couriers

The full year effect of these pressures are reflected in the forecast outturn. Combining these with the planned productivity savings in collections that will no longer be delivered and the latest resourcing plans to increase headcount in response to the ongoing stock challenge, Blood Supply are expected to finish the year significantly higher than budget.

£180.00 £160.00 £140.00 £100.00 £80.00 £60.00 £40.00 £20.00

Group Services - February 2023

Group Services	W	ΓE	Year t	o Date Act	tual	Full	Year Foreca	ist
(£)m	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			11.4	10.3	(1.1)	12.4	11.2	(1.2)
Group Services Income			1.5	1.9	0.3	1.7	1.9	0.2
Medical			1.5	1.6	0.1	1.6	1.7	0.1
Research & Development			2.6	2.1	(0.4)	2.8	2.8	0.0
Total Income			17.0	15.9	(1.1)	18.5	17.6	(0.9)
Chief Executive and Board	4	4	(0.7)	(0.7)	(0.0)	(0.8)	(0.8)	(0.0)
Donor Experience	191	182	(22.2)	(22.1)	0.2	(23.9)	(25.8)	(1.9)
Quality	130	132	(7.9)	(7.6)	0.3	(8.6)	(8.4)	0.3
Estates & Facilities	80	77	(45.0)	(45.4)	(0.4)	(49.0)	(49.7)	(0.7)
Finance	111	99	(6.7)	(6.7)	0.0	(7.3)	(7.5)	(0.2)
Strategy and Transformation	14	11	(0.9)	(1.0)	(0.0)	(1.0)	(1.1)	(0.0)
People	154	155	(10.1)	(10.2)	(0.1)	(11.0)	(11.5)	(0.4)
Digital, Data and Technology Services	301	278	(39.6)	(36.6)	3.0	(44.3)	(40.7)	3.6
Research & Development	47	34	(5.8)	(5.3)	0.5	(6.3)	(6.2)	0.1
Medical	193	178	(16.4)	(16.2)	0.2	(18.0)	(17.4)	0.7
Miscellaneous and Capital Charges	0	0	(11.5)	(12.4)	(0.9)	(12.5)	(14.0)	(1.5)
Total Expenditure	1,222	1,149	(166.9)	(164.2)	2.7	(182.9)	(183.1)	(0.1)
Operating Surplus/(Deficit)	1,222	1,149	(149.9)	(148.3)	1.6	(164.4)	(165.5)	(1.1)
	,							
Change Programme	0	35	(15.6)	(6.4)	9.3	(17.0)	(10.8)	6.2
Group Services Surplus/(Deficit)	1,222	1,185	(165.5)	(154.7)	10.8	(181.4)	(176.3)	5.2

Year to date, Group Services (excluding the Change Programme) is reporting a £1.6m positive variance against plan. This predominantly reflects underspends reported in DDTS, driven by unfilled vacancies (23 under established) and the re-categorisation of BTM expenditure to capital.

The latest forecast implies that, this position will deteriorate, with increased pressures profiled into March;

- Estate development works profiled towards in the end of the year (-£0.3m)
- BAU direct marketing catch up and increased activity to support Blood stocks levels (-£2.1m)

- selling of Annual Leave (-£0.4m)

The latest transformation plan is currently sitting at c£9.7m, due to the re-categorisation of Blood Technology Modernisation and the reprofiling of Colindale Estates costs into 2023/24.

Clinical Services - February 2023 (operating contributions - pre ABC analysis)

	14/77		Manufa Da	A - (E-113	(F	
(£)m	WTE Budget	Actual	Year to Da Budget Act		Budget	Year Forecast Fcst. Variance	
Ded Cell Immunchemetelem: (inc Descente and IDCDL)	Budgot	riotaai	Budget		Dudget	root. Vananoo	At the end of February, Clinical Services (pre ABC analysis) is reporting £1.2m ahead
Red Cell Immunohematology (inc Reagents and IBGRL)			20.6	20.7 0.1	22.6	22.5 (0.1)	of plan (excluding change programme). This is predominately driven by higher
Expenditure				(15.1) 0.7	(17.2)	(16.6) 0.6	income across H&I and TAS combined with vacancies reported within the Division.
RCI - direct contribution	250	235	4.8	5.6 0.8	5.3	5.9 0.6	
	200	200	4.0	5.0 0.0	0.0	5.5 0.0	Summary by Business Unit:
Histocompatibility & Immunogenetics							DCI, driven primerily by unfilled vegeneige
Income			14.5	15.2 0.7	16.0	16.7 0.8	RCI; driven primarily by unfilled vacancies.
Expenditure				(14.4) 0.0	(15.7)	(16.0) (0.3)	H&I contribution above plan driven by strong Solid Organ and Diseased Association
H&I - direct contribution	179	180	0.2	0.9 0.7	0.3	0.7 0.4	Investigation activity year to date. The latest forecast implies that the higher income run
Hai - direct contribution	179	100	0.2	0.9 0.7	0.3	0.7 0.4	rate will continue over the remainder of the year, offset by expenditure.
Pathology Total - WTE / direct contribution	429	414	5.0	6.4 1.5	5.6	6.6 1.0	
Pathology Total • WTE / direct contribution	429	414	5.0	0.4 1.5	5.0	0.0 1.0	TAS; year to date, TAS are reporting favourable activity variances in Photopheresis and
Therapeutic Apheresis Services							Red Cell exchange, resulting in a positive position against plan. The forecast expects
Income			10.8	12.5 1.8	11.8	13.5 1.6	activity to remain in line with plan for the final months of the year.
Expenditure			(8.6)	(9.5) (0.9)	(9.4)	(10.4) (1.0)	CDC, advance position anningtalon due to alignous in high uplus contracts. The income
TAS - direct contribution	99	100	2.2	3.0 0.8	2.5	3.1 0.6	CBC; adverse position against plan due to slippages in high value contracts. The income
		100	2.12	0.0	2.0	0.1	position looks to improve as the forecast expects a further £1.0m to be received in March.
							Cord Blood Bank and Bone Marrow Registry; Both cord blood issues and BBMR harvest
Cord Blood Bank and Brtish Bone Marrow Registry				<u> </u>			behind plan. The latest forecast does not expect Cord activity to achieve plan generating a
Income - prices			7.0	6.1 (0.9)	7.6	7.0 (0.6)	worsening year end position.
Expenditure			(3.1)	(2.9) 0.2	(3.4)	(3.1) 0.3	
SCGT - direct contribution	46	45	3.9	3.2 (0.6)	4.2	3.9 (0.3)	CMT; reduced income relating to ACT projects being delayed into 2023/24, however, this
CBC							is more than offset by reduced non pay and vacancies through CMT.
Income			4.0	2.1 (1.9)	4.4	3.3 (1.1)	
Expenditure			(3.3)	(3.9) (0.6)	(3.6)	(3.8) (0.2)	
CBC - direct contribution	37	31	0.7	(1.7) (2.5)	0.8	(0.5) (1.3)	
Cellular & Molecular Therapies (exc CBC)			L I		L		Income growth in Clinical Convince
			40.7	10.7 (0.0)	14.4	14.0 (0.5)	Income growth in Clinical Services
Income			(9.6)	12.7 (0.0) (8.7) 0.8	(10.4)	14.0 (0.5) (9.8) 0.7	90,000
Expenditure CMT I&E	108	107	(9.6)	(8.7) 0.8 3.9 0.8	(10.4) 4.0	(9.8) 0.7 4.2 0.2	80,000
							70,000
CAGT Total - WTE / direct contribution	290	283	9.9	8.5 (1.4)	11.4	10.7 (0.7)	
Transfusion excl. R&D / Medical (within Group Services)	39	36	(1.1)	(0.8) 0.3	(1.2)	(1.4) (0.2)	50,000
							40,000
DTS Management	44	36	(4.4)	(3.6) 0.8	(4.8)	(4.1) 0.7	30,000
	LL		L	I	L	I	20,000
TOTAL - WTE / Operating Surplus/(Deficit)	803	770	9.4	10.5 1.2	11.1	11.8 0.8	10,000
TOTAL - WTL / Operating Surplus (Denoid)	003	110	3.4	10.5		11.0 0.0	10,000
				I			O Actual Actual Actual Actual Budget
Change Programme	0	7	0.0	(1.5) (1.5)	(3.8)	(2.2) 1.5	16/17 17/18 18/19 19/20 20/21 21/22 22/23
							TAS H&I = RCI IBGRL SCICMT CBC SCIDT
TOTAL - WTE / Clinical Services Surplus/(Deficit)	803	776	9.4	9.0 (0.3)	7.3	9.6 2.3	
							Note: Excludes Medical and R&D funding

Note: Excludes Medical and R&D funding.

Organ Donation and Transplant – February 2023

ODT I&E	WT	E	Year t	o Date Ac	tual	Full	ear Foreca	ast
(£)m	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			63.6	66.4	2.8	69.4	72.5	3.1
Other UK Health Authorities Funding			11.6	12.9	1.4	12.6	14.1	1.5
NHSE Funding			3.1	3.2	0.1	3.4	3.6	0.2
Total Funding			78.3	82.6	4.3	85.4	90.2	4.8
Operating Expenditure	490	473	(65.1)	(64.3)	0.9	(71.9)	(70.7)	1.2
Transformation	30	25	(4.0)	(6.6)	(2.6)	(4.5)	(8.1)	(3.6)
Total Expenditure	520	498	(69.1)	(70.9)	(1.7)	(76.4)	(78.8)	(2.4)
ODT Surplus/(Deficit)	520	498	9.2	11.7	2.5	9.0	11.4	2.4
Direct contribution to Group Services						(10.8)	(10.8)	0.0
ODT Deficit (funded by cash)						(1.8)	0.6	2.3

The ODT budget envelope for 2022/23 is based on flat funding from DHSC. The resulting deficit at operational level (\pounds 1.8m).

At Q3, the forecast reported a small surplus of c£0.6m, predominately driven by an incremental increase in funding from the devolved nations combined with lower than plan activity. Since Q3, this surplus has increased further (+£0.6m), driven by the reprofiling of transformational spend into 2023/24.

Going into 2023/24 the underlying deficit is set to increase further, reflecting incremental uplifts to inflation versus flat funding over the SR21 period. Discussions are on-going with DHSC to confirm how this operating deficit will be funded c£3.1m.

Tissue and Eye Services – February 2023

Year to date, TES are reporting an income shortfall against plan, primarily driven by lower Cornea issues. Latest forecasts imply this will deteriorate further, resulting in a full year contribution shortfall of $c\pounds 1.9m$ – with the incremental pressure driven by higher usage of overtime to maintain service.

TES I&E	WT	E	Year t	o Date Act	tual	Full Year Forecast			
(£)m	Bud.	Per Act.	Bud.	Act.	Var.	Budget	Fcst.	Variance	
Income			16.8	15.4	(1.4)	18.5	16.7	(1.8)	
Cost of Sales			(0.5)	(0.5)	0.0	(0.5)	(0.5)	0.0	
Expenditure	153	150	(11.5)	(11.6)	(0.1)	(12.5)	(12.5)	0.1	
Surplus/(Deficit)	153	150	4.9	3.3	(1.6)	5.4	3.8	(1.7)	

Plasma for Medicine - February 2023

Plasma for Medicine	WT	E	Ye	ar to Date		Full	Full Year Forecast			
(£)m	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.		
Programme Funding			12.9	12.0	(0.9)	14.1	8.6	(5.5)		
Plasma for Diagnostics Income			6.8	8.4	1.6	7.5	9.8	2.3		
Expenditure	122	149	(9.7)	(10.6)	(0.9)	(16.5)	(13.7)	2.8		
Programme Surplus/(Deficit)	122	149	10.1	9.8	(0.3)	5.1	4.8	(0.3)		

For 2022/23, the Plasma plan is fully funded by a combination of cash reserves and Plasma for Diagnostics income.

The 2022/23 budget envelope estimated a group service contribution of \pounds 5.1m, however, ABC analysis/allocation has resulted in an overhead allocation of \pounds 4.8m. The balance (\pounds 0.3m) will be treated as increased funding carried forward into 2023/24.

Cash Flow – as at February 2023

	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Forecast	
	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23	Total
	£k	£k	£k	£k	£k	£k	£k	£k	£k	£k	£k	£k	£k
Opening bank balance	64,676	72,432	75,293	69,908	89,346	85,291	85,549	78,791	69,852	70,006	70,314	64,750	64,676
Receipts													
Debtors & Other Receipts	33,604	39,970	34,671	34,788	36,027	37,197	40,547	37,162	34,382	40,097	41,146	42,026	451,617
Revenue Cash Limit	0	0	0	23,833	5,958	5,958	5,958	5,958	5,958	0	0	17,875	71,500
Revenue Cash Limit - Pensions Uplift	0	0	0	3,680	920	935	935	935	935	935	935	990	11,200
Revenue Cash Limit - DCD Hearts	0	0	0	0	0	0	0	0	0	0	0	3,600	3,600
Capital Cash Limit	0	0	0	3,000	0	0	0	0	0	2,000	0	5,500	10,500
Total Receipts	33,604	39,970	34,671	65,301	42,905	44,090	47,440	44,055	41,276	43,032	42,081	69,992	548,417
Payments													
Staff Expenses	6,743	21,016	21,338	21,413	20,986	23,460	24,359	22,692	22,247	22,195	22,521	35,286	264,256
Other Revenue Payments	18,359	15,949	18,378	24,022	25,932	19,396	18,999	30,232	17,557	20,282	23,777	37,169	270,053
Capital Charges Less DH Credit Due	0	0	0	0	0	0	10,437	0	0	0	0	10,437	20,874
Capital Payments	746	144	340	427	42	975	403	70	1,317	249	1,346	4,440	10,500
Total Payments	25,848	37,109	40,055	45,863	46,961	43,832	54,198	52,995	41,121	42,725	47,644	87,332	565,683
Closing bank balance	72,432	75,293	69,908	89,346	85,291	85,549	78,791	69,852	70,006	70,314	64,750	47,410	47,410
													- I
Debtor Days (Target is 22 days)	17	14	13	18	17	19	17	14	19	21	18		
YTD BPPC By Value % (Target is 95%)	86.9%	91.1%	93.5%	94.6%	93.4%	93.7%	93.8%	93.6%	93.6%	93.8%	93.7%		
YTD BPPC By Number % (Target is 95%)	92.8%	93.1%	93.3%	93.5%	93.4%	93.3%	93.2%	93.0%	93.1%	93.1%	92.9%		↓
	1-30 Days	31-60 Days	61-90 Days	>90 Days	Total								
Overdue Debtors NBS/ODT £000's	overdue	overdue	overdue	overdue	Overdue					Math	anal Callt		C

Overdue Debtors NBS/ODT £000's	overdue	overdue	overdue	overdue	Overdue	
Total Overdue Debtors	£000's 5.745	£000's 972	£000's 198	£000's 618	£000's 7.533	
	5,145	512	150	010	1,000	

	Dec	:-22	Jan	-23
Top 5 > 90 days Overdue Debtors £000's	>90 Days overdue £000's	Total Overdue £000's	>90 Days overdue £000's	Total Overdue £000's
BARTS HEALTH NHS TRUST	102	380	144	232
KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST	51	76	51	76
SOUTH AFRICAN BONE MARROW REGISTRY			27	38
HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST	35	49	27	30
GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST			21	38
IMPERIAL COLLEGE HEALTHCARE NHS TRUST	101	403		
	50	164		
Total 5 Overdue Debtors	339	1,073	270	414
Other Debtors	300	5,758	348	7,119
Total Overdue Debtors	639	6,831	618	7,533

Notional Split	£m
Blood	13.7
Clinical Services	7.9
ODT	11.3
Plasma	14.6
NHSBT Total	47.4

>90 DAYS OVERDUE	Profile by Month											
	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual
Target Range Between £0.5m and £1.0m	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s
Ledger Balance at month end	330	413	686	680	536	922	709	673	612	639	618	

Contribution Statement– as at February 2023

Post allocation of costs via the ABC model

	Blood &		Patho	logy		CA	GT				
Year to date Actual £m	Components inc. R&D	Plasma	RCI	H&I	СМТ	CBC	SCDT	TAS	TES	ODT	NHSBT
Income/Funding											
Prices	284.0	0.0	19.6	13.2	12.2	0.0	3.8	12.1	14.9	0.0	359.8
Central Funding from DHAs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.4	12.4
Grant in Aid (DHSC Funding)	8.8	12.1	0.2	1.7	0.1	0.0	2.3	0.1	0.6	67.3	93.2
Other	6.0	8.4	1.0	0.5	0.4	2.1	0.1	0.4	0.0	3.7	22.6
Total Income/Funding	298.8	20.5	20.8	15.3	12.8	2.2	6.2	12.6	15.5	83.5	488.1
Expenditure											
Variable Costs	(33.8)	(0.7)	(1.7)	(3.7)	(2.1)	(1.5)	(0.3)	(3.8)	(2.5)	(3.2)	(53.2)
Variable Contribution	264.9	19.8	19.1	11.6	10.7	0.7	5.9	8.9	13.0	80.3	434.9
Direct Costs	(121.5)	(7.0)	(12.2)	(7.5)	(6.6)	(2.5)	(3.4)	(5.5)	(10.1)	(63.8)	(239.9)
Direct Contribution	143.5	12.9	6.9	4.1	4.1	(1.7)	2.5	3.4	2.9	16.5	195.0
Direct Support Costs	(101.5)	(2.8)	(5.1)	(2.0)	(4.4)	(0.9)	(1.6)	(1.3)	(3.2)	(10.0)	(132.9)
Total Allocated Costs	(256.8)	(10.4)	(19.0)	(13.2)	(13.1)	(4.8)	(5.3)	(10.6)	(15.8)	(77.0)	(425.9)
Total Unallocated Costs	(22.8)	(1.2)	(1.7)	(1.2)	(1.2)	(0.4)	(0.5)	(0.9)	(1.4)	(7.2)	(38.4)
Operating Net Surplus / (Deficit)	19.2	8.9	0.1	1.0	(1.5)	(3.1)	0.3	1.1	(1.7)	(0.8)	23.7
Transformation	(6.4)	(2.9)	(0.5)	(0.3)	(0.3)	(0.1)	(0.2)	(0.3)	-	(6.6)	(17.5)
Net Surplus / (Deficit) Inc Transformation	12.8	5.9	(0.3)	0.7	(1.8)	(3.1)	0.2	0.8	(1.7)	(7.4)	6.2
Budget	10.3	5.9	(0.8)	0.2	(2.8)	(0.7)	1.0	0.4	(0.5)	(10.8)	2.2
Variance	2.5	0.1	0.4	0.5	1.0	(2.4)	(0.8)	0.4	(1.2)	3.4	4.0
RAG	G	G	G	G	G	R	R	G	R	G	G

Notes;

Blood at "Green" but results from the reduced change programme plan.

CBC – adverse position against plan due to slippages in high value contracts Stem Cell and Donation – reporting red as BBMR income and CBB issues are behind plan.

TES – reporting red reflecting lower cornea activity.